head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2019, vol. 25, issue3
Subject Area: Medicine
DOI: 10.5272/jimab.2019253.2611
Published online: 22 July 2019

Original article

J of IMAB. 2019 Jul-Sep;25(3):2611-2616;
Tihomir Totev1ORCID logo Corresponding Autoremail, Grigor Gorchev2ORCID logo, Slavcho Tomov2ORCID logo,
1) Institute of Science and Research, Medical University - Pleven, Bulgaria.
2) Oncogynaecology Clinic, University Hospital, Medical University - Pleven, Bulgaria.

Purpose: The aim of the study was to establish a loss of ARID 1A protein expression in cases of ovarian endometriomas and its probable role in the development of clear-cell and endometrioid ovarian carcinomas.
Material and Methods: The immunohistochemical analysis of ARID 1A protein expression was performed on specimens collected from the study group (group 1) that included 72 patients with endometrioid ovarian cysts. The control group (group 2) included 15 patients with clear-cell and endometrioid ovarian carcinomas.
Results: In the study group, 1 of 72 specimens (1,4%) showed a complete absence of reactivity and was defined as ARID 1A protein deficient. In the control group, 5 of 15 specimens (33.3%) were found to be ARID 1A protein deficient. In 7 (46.7%) cases of this group, together with the malignant component adjacent endometriosis was diagnosed. Two of these endometrioses were atypical, with an ARID 1A protein deficient expression.
Conclusions: These data confirm the hypothesis that in some endometriomas mutation of the tumor-suppressor ARID 1A gene occur, leading to the loss of protein expression and its functional activity, thus indicating a high risk for the development of endometriosis-associated ovarian cancer.

Keywords: ARID 1A, endometrioma, endometriosis-associated ovarian carcinomas (EAOCs), ovarian clear-cell carcinoma (OCCC), endometrioid ovarian carcinoma (EnOC),

pdf - Download FULL TEXT /PDF 1795 KB/
Please cite this article as: Totev T, Gorchev G, Tomov S. Loss of ARID 1A protein expression in ovarian endometriomas as a probable predisposition to development of endometriosis-associated ovarian carcinomas. J of IMAB. 2019 Jul-Sep;25(3):2611-2616. DOI: 10.5272/jimab.2019253.2611

Corresponding AutorCorrespondence to: Tihomir P. Totev MD, PhD; St. Marina University Hospital, Department of Gynecology; Bulgarska aviatsia str. Pleven 5800, Bulgaria; E-mail: t.totev@mail.bg

1. Bulun SE. Endometriosis. N Engl J Med. 2009 Jan 15;360(3):268-79. [PubMed] [Crossref]
2. Giudice LC, Kao LC. Endometriosis. Lancet. 2004 Nov 13-19;364(9447):1789-99. [PubMed]
3. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 2003 Jul;189(1):280–94. [PubMed]
4. Somigliana E, Vigano’ P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol. 2006 May;101(2):331-41. [PubMed]
5. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010 Oct 14;363(16):1532–43. [PubMed] [Crossref]
6. Wang X, Nagl NG Jr, Flowers S, Zweitzig D, Dallas PB, Moran E. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer. 2004 Nov 20;112(4):636. [PubMed]
7. Reisman D, Glaros S, Thompson EA. The SWI/SNFcomplex and cancer. Oncogene. 2009 Apr 9;28(14):1653–68. [PubMed] [Crossref]
8. Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet. Gynecol. 1979 Mar;53(3):318–23. [PubMed]
9. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum. Pathol. 1988 Sep;19(9):1080–84. [PubMed]
10. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology. 1997 Mar;30(3):249–55. [PubMed]
11. Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, et al. Loss of ARID 1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod. Patol. 2012 Jun;25(6):885-92. [PubMed] [Crossref]
12. Maeda D, Mao TL, Fukayama M, Nakagawa S, Yano T,Taketani Y, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci. 2010;11(12):5120 –28. [PubMed] [Crossref]
13. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID 1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Patol. 2012 Apr;25(4):615-24 [PubMed] [Crossref]
14. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control. 2008 Dec;19(10):1357–64. [PubMed] [Crossref]
15. Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013 Mar 6;14(3):5367-79. [PubMed] [Crossref]
16. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997 Mar;176(3):572–79. [PubMed]
17. Koebel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010 May;29(3):203–211. [PubMed] [Crossref]
18. Anglesio MS, Carey MS, Koebel M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 2011 May 1;121(2):407–15. [PubMed] [Crossref]
19. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008 Apr;99(4):653–58. [PubMed] [Crossref]
20. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T. et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000 Jun 1;88(11):2584–89. [PubMed].

Received: 05 December 2018
Published online: 22 July 2019

back to Online Journal